ACONW
Aclarion, Inc.
Price Chart
Latest Quote
$0.04
Current Price| Previous Close | $0.04 |
| Open | $0.05 |
| Day High | $0.04 |
| Day Low | $0.03 |
| Volume | 1,337 |
Stock Information
| Cash Equivalents | $11.38M |
| Revenue | $67K |
| Net Income | $-7.39M |
| EPS (TTM) | $-6.58 |
| Exchange | NCM |
📊 Custom Metrics & Score
Score: 11/42| Debt to Equity | 1.19 |
| Debt to Earnings | -29.63 |
| Current Ratio | 0.71 |
| Quick Ratio | 0.41 |
| Avg Revenue Growth | -6.04% |
| Profit Margin | -15293.78% |
| Return on Equity | -720.88% |
| Avg FCF Growth | 30.89% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-01-30 | $0.04 | 1,337 |
About Aclarion, Inc.
Aclarion, Inc. operates as a healthcare technology company in the United States. The company uses magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. It develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The company also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and data transfer products, including AMBRA Healthcare, an imaging data transfer platform and NOCIWEB, a custom developed web-interface. In addition, it offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
📰 Latest News
Aclarion Second Quarter 2025 Earnings: Misses Expectations
Simply Wall St. • 2025-08-16T13:34:32Z
Aclarion announces expansion plans with RadNet affiliates in NY, NJ
TipRanks • 2025-03-07T14:45:44Z
Why Is Healthcare Technology Company Aclarion Stock Rocketing Premarket On Monday?
Benzinga • 2025-03-03T12:59:52Z
Aclarion, Inc. (ACON) to Showcase NOCISCAN’s Impact on Spine Surgery at 2025 Spine Summit
Insider Monkey • 2025-02-20T17:35:52Z
Aclarion, Inc. (ACON) Showcases AI-Powered NOCISCAN for Chronic Back Pain Diagnosis at Selby Spine Conference
Insider Monkey • 2025-02-04T19:19:14Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Reconciled Cost Of Revenue | $84,658 | $75,728 | $65,298 | $69,175 |
| Cost Of Revenue | $84,658 | $75,728 | $65,298 | $69,175 |
| Total Revenue | $45,724 | $75,404 | $60,444 | $60,292 |
| Operating Revenue | $45,724 | $75,404 | $60,444 | $60,292 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Expense | $535,470 | $608,288 | $1,507,546 | $476,479 |
| Total Expenses | $5,558,771 | $4,952,529 | $5,622,812 | $3,014,130 |
| Other Income Expense | $-944,728 | $573,867 | $-1,190 | $-1,519,973 |
| Other Non Operating Income Expenses | $-212,453 | $265 | - | $-1,897,175 |
| Net Non Operating Interest Income Expense | $-535,152 | $-608,116 | $-1,505,035 | $-476,479 |
| Interest Expense Non Operating | $535,470 | $608,288 | $1,507,546 | $476,479 |
| Operating Expense | $5,474,113 | $4,876,801 | $5,557,514 | $2,944,955 |
| Selling And Marketing Expense | $976,554 | $757,004 | $498,003 | $330,814 |
| General And Administrative Expense | $3,608,793 | $3,245,317 | $3,990,719 | $1,825,491 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-6,992,927 | $-4,911,374 | $-7,068,593 | $-4,950,290 |
| Net Interest Income | $-535,152 | $-608,116 | $-1,505,035 | $-476,479 |
| Interest Income | $318 | $172 | $2,511 | - |
| Normalized Income | $-6,048,199 | $-5,484,976 | $-7,067,403 | $-5,327,492 |
| Net Income From Continuing And Discontinued Operation | $-6,992,927 | $-4,911,374 | $-7,068,593 | $-4,950,290 |
| Total Operating Income As Reported | $-5,513,047 | $-4,875,981 | $-5,561,568 | $-2,953,038 |
| Net Income Common Stockholders | $-7,052,602 | $-4,911,374 | $-7,484,116 | $-5,955,888 |
| Net Income | $-6,992,927 | $-4,911,374 | $-7,068,593 | $-4,950,290 |
| Net Income Including Noncontrolling Interests | $-6,992,927 | $-4,911,374 | $-7,068,593 | $-4,950,290 |
| Net Income Continuous Operations | $-6,992,927 | $-4,911,374 | $-7,068,593 | $-4,950,290 |
| Pretax Income | $-6,992,927 | $-4,911,374 | $-7,068,593 | $-4,950,290 |
| Special Income Charges | $-1,279,712 | $0 | $0 | $378,511 |
| Interest Income Non Operating | $318 | $172 | $2,511 | - |
| Operating Income | $-5,513,047 | $-4,877,125 | $-5,562,368 | $-2,953,838 |
| Gross Profit | $-38,934 | $-324 | $-4,854 | $-8,883 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-5,319,591 | $-4,714,017 | $-5,416,236 | $-4,664,625 |
| Total Unusual Items | $-944,728 | $573,602 | $-1,190 | $377,202 |
| Total Unusual Items Excluding Goodwill | $-944,728 | $573,602 | $-1,190 | $377,202 |
| Reconciled Depreciation | $193,138 | $162,671 | $143,621 | $186,388 |
| EBITDA (Bullshit earnings) | $-6,264,319 | $-4,140,415 | $-5,417,426 | $-4,287,423 |
| EBIT | $-6,457,457 | $-4,303,086 | $-5,561,047 | $-4,473,811 |
| Diluted NI Availto Com Stockholders | $-7,052,602 | $-4,911,374 | $-7,484,116 | $-5,955,888 |
| Preferred Stock Dividends | $59,675 | - | $415,523 | $1,005,598 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Other Special Charges | $1,279,712 | - | - | $-378,511 |
| Gain On Sale Of Security | $334,984 | $573,602 | $-1,190 | $-1,309 |
| Other Taxes | $0 | $1,144 | $800 | $800 |
| Research And Development | $888,766 | $873,336 | $1,067,992 | $787,850 |
| Selling General And Administration | $4,585,347 | $4,002,321 | $4,488,722 | $2,156,305 |
| Other Gand A | $3,608,793 | $3,245,317 | $3,990,719 | $1,825,491 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $-323,648 | $-1,896,618 | $1,015,751 | $-6,873,944 |
| Total Assets | $2,123,483 | $2,459,774 | $2,914,629 | $1,889,465 |
| Total Non Current Assets | $1,299,204 | $1,170,405 | $1,213,553 | $1,157,261 |
| Goodwill And Other Intangible Assets | $1,293,705 | $1,168,623 | $1,210,207 | $1,144,625 |
| Other Intangible Assets | $1,293,705 | $1,168,623 | $1,210,207 | $1,144,625 |
| Current Assets | $824,279 | $1,289,369 | $1,701,076 | $732,204 |
| Other Current Assets | $4,165 | $41,635 | $49,564 | $273,394 |
| Current Deferred Assets | $119,730 | $100,588 | $0 | $0 |
| Restricted Cash | $10,000 | $10,000 | $10,000 | $20,000 |
| Prepaid Assets | $218,397 | $102,653 | $150,053 | $273,394 |
| Receivables | $18,326 | $13,424 | $18,653 | $6,280 |
| Accounts Receivable | $18,326 | $13,270 | $18,569 | $6,280 |
| Allowance For Doubtful Accounts Receivable | $0 | $0 | $0 | $0 |
| Gross Accounts Receivable | $18,326 | $13,270 | $18,569 | $6,280 |
| Cash Cash Equivalents And Short Term Investments | $453,661 | $1,021,069 | $1,472,806 | $432,530 |
| Cash And Cash Equivalents | $453,661 | $1,021,069 | $1,472,806 | $432,530 |
| Other Receivables | - | $154 | $84 | - |
| Cash Financial | - | $1,021,069 | $1,472,806 | $432,530 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Debt | - | $104,655 | - | $1,567,470 |
| Total Debt | - | $1,125,724 | - | $2,000,000 |
| Current Debt And Capital Lease Obligation | - | $1,125,724 | - | $2,000,000 |
| Current Debt | - | $1,125,724 | - | $2,000,000 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $1,153,426 | $3,187,769 | $688,671 | $7,618,784 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $0 |
| Current Liabilities | $1,153,426 | $3,187,769 | $688,671 | $7,618,784 |
| Other Current Liabilities | $92,641 | $443,788 | $345,242 | - |
| Current Notes Payable | $0 | $1,125,724 | $0 | $2,000,000 |
| Payables And Accrued Expenses | $610,307 | $1,263,177 | $522,717 | $5,618,784 |
| Interest Payable | $0 | $98,685 | $0 | $356,219 |
| Payables | $531,603 | $760,535 | $462,202 | $4,922,202 |
| Other Payable | $6,021 | $1,714 | $4,644 | $5,758 |
| Accounts Payable | $525,582 | $758,821 | $457,558 | $1,059,546 |
| Dividends Payable | - | - | $0 | $3,856,898 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $970,057 | $-727,995 | $2,225,958 | $-5,729,564 |
| Total Equity Gross Minority Interest | $970,057 | $-727,995 | $2,225,958 | $-5,729,319 |
| Stockholders Equity | $970,057 | $-727,995 | $2,225,958 | $-5,729,319 |
| Retained Earnings | $-51,262,311 | $-44,281,526 | $-39,370,153 | $-31,886,036 |
| Preferred Stock Equity | - | - | - | $245 |
| Preferred Securities Outside Stock Equity | - | - | - | $7,102,287 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $1,369 | $91 | $54 | $49 |
| Share Issued | $1,369 | $91 | $54 | $49 |
| Tangible Book Value | $-323,648 | $-1,896,618 | $1,015,751 | $-6,874,189 |
| Invested Capital | $970,057 | $397,729 | $2,225,958 | $-3,729,564 |
| Working Capital | $-329,147 | $-1,898,400 | $1,012,405 | $-6,886,580 |
| Total Capitalization | $970,057 | $-727,995 | $2,225,958 | $-5,729,319 |
| Additional Paid In Capital | $52,232,368 | $43,553,531 | $41,596,106 | $26,156,463 |
| Capital Stock | $0 | $0 | $5 | $254 |
| Common Stock | $0 | $0 | $5 | $9 |
| Pensionand Other Post Retirement Benefit Plans Current | $450,478 | $355,080 | $165,954 | - |
| Current Accrued Expenses | $78,704 | $502,642 | $60,515 | $696,582 |
| Net PPE | $5,499 | $1,782 | $3,346 | $12,636 |
| Accumulated Depreciation | $-54,799 | $-53,400 | $-70,026 | $-100,591 |
| Gross PPE | $60,298 | $55,182 | $73,372 | $113,227 |
| Machinery Furniture Equipment | $60,297 | $55,182 | $55,182 | $95,037 |
| Treasury Shares Number | - | $0 | $0 | - |
| Preferred Stock | - | $0 | $0 | $245 |
| Other Properties | - | - | $18,190 | $18,190 |
| Line Of Credit | - | - | - | $0 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-5,593,546 | $-3,766,469 | $-5,157,982 | $-2,501,954 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-5,271,609 | $-3,646,947 | $-4,949,112 | $-2,399,949 |
| Cash Flow From Continuing Operating Activities | $-5,271,610 | $-3,646,946 | $-4,949,113 | $-2,399,949 |
| Operating Gains Losses | $-223,105 | $-573,457 | $3,789 | $-343,118 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-321,937 | $-119,522 | $-208,870 | $-102,005 |
| Investing Cash Flow | $-321,937 | $-119,522 | $-207,870 | $-102,005 |
| Cash Flow From Continuing Investing Activities | $-321,937 | $-119,522 | $-207,870 | $-102,005 |
| Net Other Investing Changes | - | - | $1,000 | - |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repurchase Of Capital Stock | $0 | $-1,000 | $0 | - |
| Issuance Of Capital Stock | $6,573,075 | $1,463,949 | $8,552,318 | $0 |
| Financing Cash Flow | $5,026,138 | $3,314,732 | $6,187,258 | $2,939,500 |
| Cash Flow From Continuing Financing Activities | $5,026,138 | $3,314,732 | $6,187,258 | $2,939,500 |
| Net Other Financing Charges | $-1,245,964 | $-398,217 | $-365,060 | - |
| Net Preferred Stock Issuance | $1,000,000 | $0 | $0 | - |
| Preferred Stock Issuance | $1,000,000 | $1,000 | $0 | - |
| Net Common Stock Issuance | $5,573,075 | $1,462,949 | $8,552,318 | $0 |
| Common Stock Issuance | $5,573,075 | $1,462,949 | $8,552,318 | $0 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repayment Of Debt | $-300,973 | $0 | $-2,000,000 | $0 |
| Issuance Of Debt | $0 | $2,250,000 | $0 | $2,939,500 |
| Interest Paid Supplemental Data | $13,072 | $10,705 | - | - |
| Income Tax Paid Supplemental Data | $0 | $0 | - | - |
| End Cash Position | $463,661 | $1,031,069 | $1,482,806 | $452,530 |
| Beginning Cash Position | $1,031,069 | $1,482,806 | $452,530 | $14,984 |
| Changes In Cash | $-567,408 | $-451,737 | $1,030,276 | $437,546 |
| Preferred Stock Payments | $0 | $-1,000 | $0 | - |
| Net Issuance Payments Of Debt | $-300,973 | $2,250,000 | $-2,000,000 | $2,939,500 |
| Net Long Term Debt Issuance | $-300,973 | $2,250,000 | $-2,000,000 | $0 |
| Long Term Debt Payments | $-300,973 | $0 | $-2,000,000 | $0 |
| Long Term Debt Issuance | $0 | $2,250,000 | $0 | $2,000,000 |
| Net Intangibles Purchase And Sale | $-316,822 | $-119,522 | $-208,870 | $-102,005 |
| Net PPE Purchase And Sale | $-5,115 | $0 | $1,000 | $0 |
| Change In Working Capital | $-564,244 | $622,872 | $-616,095 | $629,272 |
| Change In Payables And Accrued Expense | $-283,852 | $662,902 | $-516,283 | $823,815 |
| Change In Accrued Expense | $-127,449 | $442,269 | $86,819 | $624,211 |
| Change In Interest Payable | $0 | $-6,190 | $200,712 | $114,404 |
| Change In Payable | $-156,403 | $220,633 | $-603,102 | $199,604 |
| Change In Account Payable | $-156,403 | $220,633 | $-603,102 | $199,604 |
| Change In Prepaid Assets | $-287,663 | $-38,539 | $-87,522 | $-210,765 |
| Change In Receivables | $7,271 | $-1,491 | $-12,290 | $16,222 |
| Changes In Account Receivables | $7,271 | $-1,491 | $-12,290 | $16,222 |
| Other Non Cash Items | $2,028,074 | $596,340 | $1,299,508 | $1,900,310 |
| Stock Based Compensation | $287,455 | $456,001 | $1,288,658 | $177,489 |
| Depreciation Amortization Depletion | $193,138 | $162,671 | $143,621 | $186,388 |
| Depreciation And Amortization | $193,138 | $162,671 | $143,621 | $186,388 |
| Amortization Cash Flow | $191,739 | $161,107 | $139,121 | - |
| Amortization Of Intangibles | $191,739 | $161,107 | $139,121 | - |
| Depreciation | $1,399 | $1,564 | $4,500 | - |
| Gain Loss On Investment Securities | $-335,033 | $-573,457 | - | $30,393 |
| Net Income From Continuing Operations | $-6,992,927 | $-4,911,374 | $-7,068,593 | $-4,950,290 |
| Proceeds From Stock Option Exercised | - | $0 | $8,552,318 | - |
| Net Short Term Debt Issuance | - | $2,250,000 | $0 | $2,939,500 |
| Short Term Debt Payments | - | $0 | $-2,000,000 | - |
| Short Term Debt Issuance | - | $2,250,000 | $0 | $2,939,500 |
| Purchase Of Intangibles | - | $-119,522 | $-208,870 | $-102,005 |
| Sale Of PPE | - | $0 | $1,000 | $0 |
| Gain Loss On Sale Of PPE | - | $0 | $3,789 | $0 |
| Purchase Of PPE | - | - | - | $0 |